Project Grant R35GM166431
Award Date 9/1/26
Completion Date 4/30/31
Dollars Obligated $443K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services National Institutes of Health, awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $393,689 in project grant funding on August 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The award funds research defining mechanisms that couple nutrient sensing to functional programs in non-malignant mammalian cells. The...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $322,382 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating cell-specific interleukin-1 receptor 1 (IL-1R1) signaling in focal and diffuse traumatic brain injury models. The research uses genetically engineered mice with precise...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1.854 million on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research into compartmentalized reactive oxygen species (ROS) sensing in the brain, specifically investigating how neurons balance mitochondrial energy production with ROS control....
- The National Institute of General Medical Sciences awarded The General Hospital Corporation (Massachusetts General Hospital) $453,750 under the Biomedical Research and Research Training program (CFDA 93.859) on August 1, 2026, through Project Grant R35GM165865. The award funds research investigating how mitochondrial metabolism regulates species-specific developmental rates in mammalian embryos. The research program uses an in vitro system that recapitulates the two- to threefold difference in...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $616,126 on August 26, 2026, to conduct in vivo genome editing research for cerebrovascular disorders under NINDS Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award funds research defining how and when gene editing can restore cerebrovascular and white matter integrity in an ACTA2 R179H...
- The National Institutes of Health Office of the Director awarded The General Hospital Corporation (Massachusetts General Hospital) $783,750 under the Trans-NIH Research Support program (CFDA 93.310) on September 1, 2026, to conduct therapeutic discovery in neurodegeneration using bioengineered organoids and artificial intelligence-driven genomics approaches. The award funds development of multiplexed differentiation strategies to generate midbrain organoids that integrate all major brain cell...
- The National Institute of General Medical Sciences awarded The General Hospital Corporation (Massachusetts General Hospital) $444,000 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop secreted genetically encoded fluorescent biosensors for in vivo extracellular imaging. The project will create a toolkit of biosensors across four research areas: imaging extracellular matrix structures by conjugating fluorescent proteins to lectins and...
- The Defense Health Agency awarded Massachusetts General Hospital a $368,238 project grant under the Military Medical Research and Development program (CFDA 12.420) from September 1, 2023 through August 31, 2026. The grant will fund research to determine if microbiome-derived cell fragments in the brain accelerate transition from traumatic brain injury to Alzheimer's disease or related dementias. As a leading academic medical center, Massachusetts General Hospital will leverage its expertise in...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $819,980.00 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on elucidating sex differences in melanoma tumorigenesis. The 3-year research project, beginning on August 15, 2024 and ending on August 14, 2027, aims to advance the understanding and treatment of this complex...
- The National Institute on Aging awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $463,000 under the Aging Research program (CFDA 93.866) on May 1, 2026, to support research investigating chromatin mechanisms of cytoplasmic chromatin fragments during senescence and aging. The research examines how chromatin fragments transit from the nucleus to the cytoplasm in senescent and aged cells, activating the cGAS-STING immune pathway and driving chronic...